Table 1 Breast Cancer Tissue Microarray: Clinicopathological Details
From: Quantifying Argonaute 2 (Ago2) expression to stratify breast cancer
| Â | Stained for Ago2 N (%) |
|---|---|
Age | |
 Pre/Peri-menopausal | 85 (29.2%) |
 Post-menopausal | 206 (70.8%) |
 Total (n=) | 291 |
Subtype | |
 Luminal A | 119 (36.3%) |
 Luminal B | 29 (8.8%) |
 Her2 positive | 18 (5.5%) |
 Basal | 60 (18.3%) |
 Unknown | 102 (31.1%) |
 Total (n=) | 328 |
Receptor Status | |
 ER Positive | 197 (64.5%) |
 ER Negative | 108 (35.4%) |
 Total (n=) | 305 |
 PR positive | 182 (60.3%) |
 PR Negative | 120 (39.7) |
 Total (n=) | 302 |
 Her2 positive | 46 (20.3%) |
 Her2 negative | 181 (79.7%) |
 Total (n=) | 227 |
Stage | |
 1 | 104 (33.1%) |
 2 | 156 (49.7%) |
 3 | 26 (8.3%) |
 4 | 28 (8.9%) |
 Total (n=) | 314 |
N Score | |
 0 | 143 (48%) |
 1 | 85 (28.5%) |
 2 | 45 (15.1%) |
 3 | 25 (8.4%) |
 Total (n=) | 298 |
Metastatic disease | |
 No | 289 (95.4%) |
 Yes | 14 (4.6%) |
 Total (n=) | 303 |